ALLK

Allakos Inc.

1.45 USD
+0.02 (+1.40%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Allakos Inc. stock is up 36.79% since 30 days ago. The next earnings date is Aug 7, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 5 May’s closed higher than April.

About Allakos Inc.

Allakos Inc. develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of gastritis and/or eosinophilic duodenitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria.